// App-Quantinova.ai

3845 : A novel selectivity determinant informs the development of next-generation stapled peptide inhibitors of anti-apoptotic BFL-1/A1

Researchers

Presenter

  • Annissa J. Huhn

Principal Investigators

  • Rachel M. Guerra

  • Gregory H. Bird

  • Loren D. Walensky

Medical Centers

  • Dana-Farber Cancer Institute, Boston, MA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Lymphomas

  • Melanoma

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Venetoclax

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved